Topline results expected in the third quarter of 2024; planning a Phase 2 Trial for prevention of kidney transplant rejection Anti-CD40L has multiple possible indications in addition to solid organ ...
TNX-1500, a third generation anti-CD40L mAb, was Fc-modified to preserve the activity and bioavailability of first generation mAbs while addressing their thrombosis risk “For more than 30 years, ...
Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the ...
CHATHAM, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has entered into ...
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 ...
CHATHAM, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from three oral ...
(MENAFN- GlobeNewsWire - Nasdaq) Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant ...
Preclinical Xenotransplantation Studies are Expected to Support Regulatory Filings for TNX-1500 CHATHAM, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results